Myomo, Inc. (BST:0M61)
| Market Cap | 29.99M +24.6% |
| Revenue (ttm) | 40.07M +9.3% |
| Net Income | -13.28M |
| EPS | -0.32 |
| Shares Out | n/a |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | n/a |
| Open | 0.7510 |
| Previous Close | 0.7630 |
| Day's Range | 0.7310 - 0.7670 |
| 52-Week Range | 0.5420 - 1.5980 |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Nov 9, 2026 |
About Myomo
Myomo, Inc., a wearable medical robotics company, designs, develops, and produces myoelectric orthotics for people with neuromuscular disorders in the United States, Germany, and internationally. The company offers MyoPro, a myoelectric-controlled upper limb brace or orthosis product used for supporting a patient’s weak or paralyzed arm to enable and improve functional activities of daily living. It also provides MyoPro 2 that includes control technology, configuration software and user interface, and pop-out battery for extended use of the bra... [Read more]
Financial Performance
In 2025, Myomo's revenue was $40.93 million, an increase of 25.73% compared to the previous year's $32.55 million. Losses were -$15.57 million, 151.9% more than in 2024.
Financial numbers in USD Financial StatementsNews
Myomo Slides: Investor presentation
Myomo has posted slides in relation to its latest quarterly earnings report, which was published on November 12, 2026.
Myomo reports Q3 EPS (10c), consensus (7c)
Reports Q3 revenue $12.3M, consensus $11.5M. “The focus on our four success pillars helped deliver record revenue and solid operating leverage in the quarter, resulting in breakeven Adjusted EBITDA an...
Myomo sees FY26 revenue in upper half of prior guidance
The company states: “We raised our full year revenue guidance last quarter, and today we are updating that revenue guidance to be in the upper half of that range. We…
Myomo Earnings Call Transcript: Q3 2026
Q3 revenue set a record at $12.3M, up 22% YoY, with 71.3% gross margin and adjusted EBITDA break-even. Recurring channels reached 54% of revenue, and FY2026 revenue guidance narrowed to $46M-$47M.
Myomo Earnings release: Q3 2026
Myomo released its Q3 2026 earnings on November 9, 2026, summarizing the period's financial results.
Myomo Quarterly report: Q3 2026
Myomo has published its Q3 2026 quarterly earnings report on November 9, 2026.
Myomo Reports Third Quarter 2026 Financial and Operating Results
BURLINGTON, Mass.--(BUSINESS WIRE)--Myomo, Inc. (NYSE American: MYO)(“Myomo” or the “Company”), a wearable medical robotics platform company that offers increased functionality for those suffering fro...
Myomo to Attend the 17th Annual Craig Hallum Alpha Select Conference
BURLINGTON, Mass.--(BUSINESS WIRE)--Myomo, Inc. (NYSE American: MYO) ("Myomo" or the "Company"), a wearable medical robotics company that offers increased functionality for those suffering from neurol...
Myomo to Report Third Quarter 2026 Financial Results on November 9
BURLINGTON, Mass.--(BUSINESS WIRE)--Myomo, Inc. (NYSE American: MYO) (“Myomo” or the “Company”), a wearable medical robotics company that offers increased functionality for those suffering from neurol...
Myomo names Mary-Katherine McClure as Chief Commercial Officer
Myomo (MYO) “announced the appointment of Mary-Katherine McClure as Chief Commercial Officer effective October 12, 2026, succeeding Micah Mitchell, who will be departing following a leadership transit...
Myomo Appoints Mary-Katherine McClure as Chief Commercial Officer
BURLINGTON, Mass.--(BUSINESS WIRE)--Myomo, Inc. (NYSE American: MYO) ("Myomo" or the "Company"), a wearable medical robotics company that offers increased functionality for those suffering from neurol...
Myomo Transcript: H.C. Wainwright 28th Annual Global Investment Conference
The company is accelerating growth through expanded referral networks, O&P channel partnerships, and new product launches, supported by improved margins and reduced cash burn. Key innovations include a hand-only device for Germany and the AI-enabled MyoPro 3.0, with clinical trials underway to support broader reimbursement.
Myomo management to meet virtually with Craig-Hallum
Virtual Meeting to be held on September 21 hosted by Craig-Hallum.
Myomo to Present at the H.C. Wainwright 28th Annual Global Investment Conference
BURLINGTON, Mass.--(BUSINESS WIRE)--Myomo, Inc. (NYSE American: MYO) ("Myomo" or the "Company"), a wearable medical robotics company that offers increased functionality for those suffering from neurol...
Myomo price target raised to $10.50 from $10 at Ascendiant
Ascendiant raised the firm’s price target on Myomo (MYO) to $10.50 from $10 and keeps a Buy rating on the shares. The company reported Q2 upside and raised its 2026…
Myomo sees Q3 revenue $11.5M-$12M, consensus $11.16M
“In the third quarter of 2026, we expect continued year-over-year revenue growth with modestly higher operating expenses on a sequential basis, as we expand our MyoConnect program. We expect third…
Myomo sees FY26 revenue $45M-$47M, consensus $44.43M
“We are raising our full year revenue guidance to $45 million to $47 million. We reiterate our full year operating leverage expectation, and we expect cash burn to be less…
Myomo reports Q2 EPS (9c), consensus (10c)
Reports Q2 revenue $11.7M, consensus $10.35M. “I am pleased to report that the evolution of our go-to-market approach is driving positive results. Revenue of $11.7 million exceeded our expectations, w...
Myomo Earnings Call Transcript: Q2 2026
Q2 2026 revenue grew 21% year-over-year to $11.7M, with recurring patient sources now 53% of revenue and gross margin up to 72.1%. Full-year guidance was raised to $45–$47M, and operating loss and cash burn improved significantly.
Myomo Earnings release: Q2 2026
Myomo released its Q2 2026 earnings on August 5, 2026, summarizing the period's financial results.
Myomo Quarterly report: Q2 2026
Myomo has published its Q2 2026 quarterly earnings report on August 5, 2026.
Myomo Reports Second Quarter 2026 Financial and Operating Results
BURLINGTON, Mass.--(BUSINESS WIRE)--Myomo, Inc. (NYSE American: MYO)(“Myomo” or the “Company”), a wearable medical robotics platform company that offers increased functionality for those suffering fro...
Myomo to Report Second Quarter 2026 Financial Results on August 5
BURLINGTON, Mass.--(BUSINESS WIRE)--Myomo, Inc. (NYSE American: MYO) (“Myomo” or the “Company”), a wearable medical robotics company that offers increased functionality for those suffering from neurol...
Myomo Transcript: IAccess Alpha Virtual Best Ideas Summer Investment Conference 2026
The presentation highlighted strong growth in recurring patient sources, expanded insurance coverage, and a multi-billion dollar market opportunity for a proprietary wearable device addressing upper limb paralysis. Financials show improving margins and operational leverage, with a clear path to $100 million in annual revenue.
Myomo Slides: Investor presentation
Myomo has posted slides in relation to its latest quarterly earnings report, which was published on June 23, 2026.